Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 27, 2025

Brilliant Violet 421(TM) anti-human CD197 (CCR7)

RRID:AB_11203894
Type: Antibody

Proper Citation

(BioLegend Cat# 353208, RRID:AB_11203894)

Antibody Information

URL: http://antibodyregistry.org/AB_11203894

Proper Citation: (BioLegend Cat# 353208, RRID:AB_11203894)

Target Antigen: CD197

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD197 (CCR7)

Description: This monoclonal targets CD197

Target Organism: human

Clone ID: Clone G043H7

Antibody ID: AB_11203894

Vendor: BioLegend

Catalog Number: 353208

Alternative Catalog Numbers: 353207

Record Creation Time: 20231110T055900+0000

Record Last Update: 20241115T053735+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD197 (CCR7).

No alerts have been found for Brilliant Violet 421(TM) anti-human CD197 (CCR7).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Hopkins G, et al. (2024) Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort). Journal of clinical immunology, 44(6), 147.

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell, 187(2), 390.

Davis-Porada J, et al. (2024) Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. Immunity, 57(12), 2895.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Ciacchi L, et al. (2023) CD4+ T cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. Immunity, 56(5), 1082.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. Journal of translational medicine, 21(1), 506.

Cao W, et al. (2023) TRIB2 safeguards naive T cell homeostasis during aging. Cell reports, 42(3), 112195.

Ols S, et al. (2023) Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity, 56(10), 2425.

Furukawa Y, et al. (2023) iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer. Cell reports. Medicine, 4(12), 101327.

Canale FP, et al. (2023) Proteomics of immune cells from liver tumors reveals immunotherapy targets. Cell genomics, 3(6), 100331.

Laliberté A, et al. (2023) Vpr attenuates antiviral immune responses and is critical for full pathogenicity of SIVmac239 in rhesus macaques. iScience, 26(12), 108351.

Nellore A, et al. (2023) A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Immunity, 56(4), 847.

Kirosingh AS, et al. (2023) Malaria-specific Type 1 regulatory T cells are more abundant in first pregnancies and associated with placental malaria. EBioMedicine, 95, 104772.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. Immunity, 56(8), 1955.

Wang X, et al. (2023) CD70-induced differentiation of proinflammatory Th1/17/22/GM lymphocytes associated with disease progression and immune reconstitution during HIV infection. Emerging microbes & infections, 12(2), 2271068.

Pan Q, et al. (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A?02:01 patients with advanced soft tissue sarcoma. Cell reports. Medicine, 4(8), 101133.

Capelle CM, et al. (2022) Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients. Cell reports. Medicine, 3(4), 100600.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 185(3), 493.

Vadaq N, et al. (2022) Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV. iScience, 25(10), 105089.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell reports, 38(2), 110235.